Telavancin Hydrochloride Patent Expiration
Telavancin Hydrochloride is Used for treating bacterial infections, including staphylococcal infections. It was first introduced by Cumberland Pharmaceuticals Inc
Telavancin Hydrochloride Patents
Given below is the list of patents protecting Telavancin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vibativ | US7531623 | Hydrochloride salts of a glycopeptide phosphonate derivative | Jan 01, 2027 | Cumberland |
| Vibativ | US6635618 | Glycopeptide phosphonate derivatives |
Sep 11, 2023
(Expired) | Cumberland |
| Vibativ | US6858584 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
Aug 24, 2022
(Expired) | Cumberland |
| Vibativ | US6872701 | Glycopeptide phosphonate derivatives |
Jun 05, 2021
(Expired) | Cumberland |
| Vibativ | US7008923 | Glycopeptide phosphonate derivatives |
May 06, 2021
(Expired) | Cumberland |
| Vibativ | US7208471 | Glycopeptide phosphonate derivatives |
May 01, 2021
(Expired) | Cumberland |
| Vibativ | US7351691 | Glycopeptide phosphonate derivatives |
May 01, 2021
(Expired) | Cumberland |
| Vibativ | US7544364 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May 01, 2021
(Expired) | Cumberland |
| Vibativ | US7700550 | Glycopeptide phosphonate derivatives |
May 01, 2021
(Expired) | Cumberland |
| Vibativ | US8101575 | Glycopeptide phosphonate derivatives |
May 01, 2021
(Expired) | Cumberland |
| Vibativ | US8158580 | Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin |
May 01, 2021
(Expired) | Cumberland |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Telavancin Hydrochloride's patents.
Latest Legal Activities on Telavancin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Telavancin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 May, 2024 | US8158580 |
| Expire Patent Critical | 26 Feb, 2024 | US8101575 |
| Maintenance Fee Reminder Mailed Critical | 04 Dec, 2023 | US8158580 |
| Maintenance Fee Reminder Mailed Critical | 11 Sep, 2023 | US8101575 |
| Expire Patent Critical | 23 May, 2022 | US7700550 |
| Maintenance Fee Reminder Mailed Critical | 06 Dec, 2021 | US7700550 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2020 | US7544364 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Sep, 2020 | US7531623 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 04 Oct, 2019 | US8158580 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Sep, 2019 | US7351691 |
Telavancin Hydrochloride's Family Patents
